Genetic polymorphisms that predict outcome and need for treatment in cardiovascular disease

Current Opinion in Critical Care

Volumn 12, Issue 5, 2006, Pages 420-425

  Yende, Sachin ^a   Wunderink, Richard G ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cardiovascular; Cardiovascular disease; Cardiovascular surgery; Genetic polymorphisms; Myocardial infarction; Pharmacogenomics; Polymorphism

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CD134 ANTIGEN; KEXIN; LOW DENSITY LIPOPROTEIN; MYOCYTE ENHANCER FACTOR 2; SERINE PROTEINASE; SUBTILISIN; TUMOR NECROSIS FACTOR;

AORTA ANEURYSM; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS SURGERY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HEART INFARCTION; HUMAN; KIDNEY DISEASE; LIPOPROTEIN BLOOD LEVEL; REVIEW; STROKE; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PEDIGREE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 33748433393     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/01.ccx.0000244120.54495.be     Document Type: Review

References (41)

1. Yende S, Quasney MW, Tolley EA, Wunderink RG. Clinical relevance of angiotensin-converting enzyme gene polymorphisms to predict risk of mechanical ventilation after coronary artery bypass graft surgery. Crit Care Med 2004; 32:922-927.
2. Volzke H, Engel J, Kleine V, et al. Angiotensin I-converting enzyme insertion/deletion polymorphism and cardiac mortality and morbidity after coronary artery bypass graft surgery. Chest 2002; 122:31-36.
3. Lloyd-Jones DM, Nam BH, D'Agostino RB Sr, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA 2004; 291:2204-2211.
4. Roldan V, Corral J, Marin F, et al. Synergistic association between hypercholesterolemia and the C46T factor XII polymorphism for developing premature myocardial infarction. Thromb Haemost 2005; 94:1294-1299.
5. Watkins H, Farrall M. Genetic susceptibility to coronary artery disease: from promise to progress. Nat Rev Genet 2006; 7:163-173. This is a recent comprehensive review of genetic factors influencing CAD.
6. Zwick ME, Cutler DJ, Chakravarti A. Patterns of genetic variation in Mendelian and complex traits. Annu Rev Genom Hum Genet 2000; 1:387-407.
7. Wang L, Fan C, Topol SE, et al. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science 2003; 302:1578-1581.
8. Bhagavatula MR, Fan C, Shen GQ, et al. Transcription factor MEF2A mutations in patients with coronary artery disease. Hum Mol Genet 2004; 13:3181-3188.
9. Gonzalez P, Garcia-Castro M, Reguero JR, et al. The Pro279Leu variant in the transcription factor MEF2A is associated with myocardial infarction. J Med Genet 2006; 43:167-169. This study identified another rare polymorphismin the Spanish population in exon 7 of the MEF2A gene that was associated with CAD.
10. •] could not explain increased risk in sporadic CAD.
11. Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock. Arch Intern Med 2002; 162:1028-1032.
12. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347:185-192.
13. Antonicelli R, Olivieri F, Cavallone L, et al. Tumor necrosis factor-alpha gene -308G>A polymorphism is associated with ST-elevation myocardial infarction and with high plasma levels of biochemical ischemia markers. Coron Artery Dis 2005; 16:489-493. This study shows that proinflammatory genes may lead to differences in presentation of acute myocardial infarction.
14. Wang X, Ria M, Kelmenson PM, et al. Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat Genet 2005; 37:365-372. This study used murine models to demonstrate that the TNFSF4 gene plays an important role in atherogenesis and then showed that genetic variants in humans in the same gene are associated with increased risk of myocardial infarction in two separate populations.
15. Ozaki K, Ohnishi Y, Iida A, et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002; 32:650-654.
16. Cohen JC, Kiss RS, Pertsemlidis A, et al. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 2004; 305:869-872.
17. Bown MJ, Horsburgh T, Nicholson ML, et al. Cytokines, their genetic polymorphisms, and outcome after abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg 2004; 28:274-280.
18. Harrap SB, Zammit KS, Wong ZYH, et al. Genome-wide linkage analysis of the acute coronary syndrome suggests a locus on chromosome 2. Arterioscler Thromb Vasc Biol 2002; 22:874-878.
19. Yamada Y, Izawa H, Ichihara S, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002; 347:1916-1923.
20. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354:1264-1272. This longitudinal study demonstrates that variants in proprotein convertase subtilisin/kexin type 9 influences LDL cholesterol and reduces incidence of coronary events even in populations with several other cardiovascular risk factors.
21. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000; 405:847-856.
22. Edfeldt K, Bennet AM, Eriksson P, et al. Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction. Eur Heart J 2004; 25:1447-1453.
23. Cardon LR, Palmer LJ. Population stratification and spurious allelic association. Lancet 2003; 361:598-604.
24. Helgadottir A, Manolescu A, Helgason A, et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006; 38:68-74.
25. Helgadottir A, Gretarsdottir S, St Clair D, et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet 2005; 76:505-509.
26. Hakonarson H, Thorvaldsson S, Helgadottir A, et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 2005; 293:2245-2256. This is an important study to potentially demonstrate how pharmacogenomics can be used to alter outcomes.
27. Andrikopoulos GK, Tzeis SM, Needham EW, et al. Lack of association between common polymorphisms in genes of the renin-angiotensin system and mortality after myocardial infarction. Cardiology 2005; 103:185-188.
28. Araujo MA, Goulart LR, Cordeiro ER, et al. Genotypic interactions of renin-angiotensin system genes in myocardial infarction. Int J Cardiol 2005; 103:27-32.
29. Armstrong PW, Collen D. Fibrinolysis for acute myocardial infarction current status and new horizons for pharmacological reperfusion, part 1. Circulation 2001; 103:2862-2866.
30. Eriksson P, Kallin B, van 't Hooft FM, et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995; 92:1851-1855.
31. Sibbing D, von Beckerath O, von Beckerath N, et al. Plasminogen activator inhibitor-14G/5G polymorphism and efficacy of reperfusion therapy in acute myocardial infarction. Blood Coagul Fibrinolysis 2005; 16:511-515.
32. Mira JP, Cariou A, Grall F, et al. Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality. JAMA 1999; 282:561-568.
33. Appoloni O, Dupont E, Vandercruys M, et al. Association between the TNF-2 allele and a better survival in cardiogenic shock. Chest 2004; 125:2232-2237.
34. Podgoreanu MV, Schwinn DA. New paradigms in cardiovascular medicine: emerging technologies and practices: perioperative genomics. J Am Coll Cardiol 2005; 46:1965-1977. An overview of how genetic markers influence outcomes of cardiovascular surgery.
35. Wan S, Marchant A, DeSmet JM, et al. Human cytokine responses to cardiac transplantation and coronary artery bypass grafting. J Thorac Cardiovasc Surg 1996; 111:469-477.
36. Schroeder S, Borger M, Wrigge H, et al. A tumor necrosis factor gene polymorphism influences the inflammatory response after cardiac operation. Ann Thorac Surg 2003; 75:534-537.
37. Stafford-Smith M, Podgoreanu M, Swaminathan M, et al. Association of genetic polymorphisms with risk of renal injury after coronary bypass graft surgery. Am J Kidney Dis 2005; 45:519-530. Clinical factors are poor predictors of post surgical renal failure. Analysis of 12 candidate genes suggested an increased risk with certain inflammatory and vasoconstrictor molecule polymorphisms.
38. Welsby IJ, Podgoreanu MV, Phillips-Bute B, et al. Genetic factors contribute to bleeding after cardiac surgery. J Thromb Haemost 2005; 3:1206-1212. Association study of genetic risk of bleeding after coronary bypass surgery. Seven of 19 candidate genes were associated with risk of bleeding.
39. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990; 9:811-818.
40. Khau VK, Mathieu F, Zhu L, et al. Mapping of familial thoracic aortic aneurysm/dissection with patent ductus arteriosus to 16p12.2-p13.13. Circulation 2005; 112:200-206. A genome-wide scan was conducted in a pedigree with family history of thoracic aneurysm to identify a susceptibility locus on chromosome 16p12.
41. Faraday N, Martinez EA, Scharpf RB, et al. Platelet gene polymorphisms and cardiac risk assessment in vascular surgical patients. Anesthesiology 2004; 101:1291-1297.